Literature DB >> 33615933

Immunotoxins and nanobody-based immunotoxins: review and update.

Mohammad Reza Khirehgesh1, Jafar Sharifi1, Fatemeh Safari2, Bahman Akbari1,3.   

Abstract

Immunotoxins (ITs) are protein-based drugs that compose of targeting and cytotoxic moieties. After binding the IT to the specific cell-surface antigen, the IT internalises into the target cell and kills it. Targeting and cytotoxic moieties usually include monoclonal antibodies and protein toxins with bacterial or plant origin, respectively. ITs have been successful in haematologic malignancies treatment. However, ITs penetrate poorly into solid tumours because of their large size. Use of camelid antibody fragments known as nanobodies (Nbs) as a targeting moiety may overcome this problem. Nbs are the smallest fragment of antibodies with excellent tumour tissue penetration. The ability to recognise cryptic (immuno-evasive) target antigens, low immunogenicity, and high-affinity are other fundamental characteristics of Nbs that make them suitable candidates in targeted therapy. Here, we reviewed and discussed the structure and function of ITs, Nbs, and nanobody-based ITs. To gain sound insight into the issue at hand, we focussed on nanobody-based ITs.

Entities:  

Keywords:  Immunotoxin; Pseudomonas exotoxin A; diphtheria toxin; nanobody; ribosome-inactivating proteins; single-domain antibody; variable fragment of heavy-chain only antibody

Mesh:

Substances:

Year:  2021        PMID: 33615933     DOI: 10.1080/1061186X.2021.1894435

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  4 in total

1.  Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".

Authors:  Jafar Sharifi; Mohammad Reza Khirehgesh; Bahman Akbari; Bijan Soleymani; Kamran Mansouri
Journal:  Mol Biotechnol       Date:  2021-03-26       Impact factor: 2.695

2.  Nanomaterial-based biosensor developing as a route toward in vitro diagnosis of early ovarian cancer.

Authors:  Yuqi Yang; Qiong Huang; Zuoxiu Xiao; Min Liu; Yan Zhu; Qiaohui Chen; Yumei Li; Kelong Ai
Journal:  Mater Today Bio       Date:  2022-02-15

Review 3.  Research progress and applications of nanobody in human infectious diseases.

Authors:  Yaxian Mei; Yuanzhi Chen; Jwala P Sivaccumar; Zhiqiang An; Ningshao Xia; Wenxin Luo
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

4.  Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.

Authors:  Sangsu Park; Minh Quan Nguyen; Huynh Kim Khanh Ta; Minh Tan Nguyen; Gunsup Lee; Chong Jai Kim; Yeon Jin Jang; Han Choe
Journal:  Int J Mol Sci       Date:  2021-06-17       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.